Medical aerosol formulation

Details Medical aerosol formulation Medical aerosol formulation

2000-10-31

2003-04-01

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Effervescent or pressurized fluid containing

Organic pressurized fluid

C424S043000, C424S044000, C514S004300, C514S866000, C514S003100, C128S200140, C128S200210, C128S200230

Reexamination Certificate

active

06540983

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a medicinal aerosol formulation, and more particularly, to a medicinal aerosol formulation comprising a &bgr;-cell or &agr;-cell hypoglycemic.
2. Description of the Related Art
Delivery of drugs to the lung by way of inhalation is an important means of treating a variety of conditions, including such common local conditions as cystic fibrosis, pneumonia, bronchial asthma and chronic obstructive pulmonary disease and some systemic conditions, including hormone replacement, pain management, immune deficiency, erythropoiesis, diabetes, etc. Steroids, &bgr;2 agonists, anti-cholinergic agents, proteins and polypeptides are among the drugs that are administered to the lung for such purposes. Such drugs are commonly administered to the lung in the form of an aerosol of particles of respirable size (less than about 10 &mgr;m in diameter). The aerosol formulation can be presented as a liquid or a dry powder. In order to assure proper particle size in a liquid aerosol, particles can be prepared in respirable size and then incorporated into a colloidial dispersion either containing a propellant as a metered dose inhaler (MDI) or air, such as in the case of a dry powder inhaler (DPI). Alternatively, formulations can be prepared in solution form in order to avoid the concern for proper particle size in the formulation. Solution formulations must nevertheless be dispensed in a manner that produces particles or droplets of respirable size.
For MDI application, once prepared an aerosol formulation is filled into an aerosol canister equipped with a metered dose valve. In the hands of the patient the formulation is dispensed via an actuator adapted to direct the dose from the valve to the patient.
What is needed and desired is a stable aerosol formulation for the treatment of diabetes and conditions related thereto.
SUMMARY OF THE INVENTION
It has surprisingly been found that a novel and stable medicinal aerosol formulation of a &bgr;-cell or &agr;-cell hypoglycemic medicament can be obtained without the use of a surfactant, such as sorbitan trioleate. A suitable &bgr;-cell hypoglycemic medicament is one selected from the group consisting of an amylin and insulin; however, other medicament agents possessing antidiabetic activity, including the &agr;-cell hypoglycemic glucagon, acetohexamide, chlorpropamide, tolazamide, tolbutamide, and glipizide, as well as any mixture of any two or three of the foregoing &bgr;-cell hypoglycemic medicaments may be generally included.


REFERENCES:
patent: 4198313 (1980-04-01), Bargigia et al.
patent: 5011678 (1991-04-01), Wang et al.
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5695744 (1997-12-01), Neale et al.
patent: 5744123 (1998-04-01), Akehurst et al.
patent: 5997848 (1999-12-01), Patton et al.
patent: 6193954 (2001-02-01), Adjei et al.
patent: WO 90 009781 (1990-09-01), None
patent: WO 96 19198 (1996-06-01), None
Patton et al., Advanced Drug Delivery Reviews, 8(1992) 179-196.

Affiliated with

Also associated with

Rating

Medical aerosol formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical aerosol formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical aerosol formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3080729